Survodutide

The design logic. Glucagon and GLP-1 come from the same precursor and have opposite effects on blood glucose. Deliberately agonising the glucagon receptor sounds like a mistake until you look at what else glucagon does: it raises energy expenditure, promotes hepatic fat oxidation and reduces liver fat. Pair it with a GLP-1 agonist strong enough to control glycaemia and you get weight loss driven from both ends - less intake and more expenditure - plus a direct action on the liver that pure incretins do not have [4].

Obesity. The phase 2 dose-finding trial randomised 386 adults to survodutide 0.6, 2.4, 3.6 or 4.8 mg weekly or placebo for 46 weeks. Mean weight changes were -6.2%, -12.5%, -13.2% and -14.9% respectively; the placebo group changed -2.8%. Adverse events affected 91% of survodutide recipients against 75% on placebo, primarily gastrointestinal [1]. A phase 3 obesity programme is underway [5][6].

Diabetes. In 413 people with type 2 diabetes over 16 weeks, survodutide reduced HbA1c by around 1.5-1.7 percentage points, comparable to open-label semaglutide 1.0 mg in the same trial - and produced greater weight loss than semaglutide at doses of 1.8 mg weekly and above [7].

The liver, which is the point. In 293 adults with biopsy-confirmed MASH and fibrosis, 48 weeks of survodutide produced improvement in steatohepatitis without worsening fibrosis in 47% at 2.4 mg, 62% at 4.8 mg and 43% at 6.0 mg, against 14% on placebo. Liver fat fell by at least 30% in 57-67% against 14%, and fibrosis improved by at least one stage in 34-36% against 22% [2]. A phase 3 trial in obesity with MASLD found 84.2% reached a 30% or greater liver fat reduction against 24.3% on placebo, with 12.2% weight loss against 1.0% [3]. Mediation analysis of the phase 2 data has since tried to separate the weight-dependent from the weight-independent liver effects [8].

A phase 1 study specifically in people with cirrhosis established tolerability and pharmacokinetics in that population [9], which matters because MASH patients are exactly who would receive it.

Survodutide is an acylated peptide agonist at both the glucagon receptor and the GLP-1 receptor, with a fatty diacid for albumin binding and weekly dosing [4]. The preclinical characterisation work set out to find a balance of the two activities that gave the metabolic benefit of glucagon without the glycaemic penalty [4].

Two arms, two mechanisms. GLP-1 reduces intake and secures glycaemic control. Glucagon raises resting energy expenditure and drives hepatic fatty acid oxidation and lipolysis. In a compound where weight is falling, the glucagon arm's tendency to raise glucose is more than offset by the GLP-1 arm and by the weight loss itself - which is why HbA1c fell rather than rose in the diabetes trial [7].

The liver effect is where the design pays off. GLP-1 agonists reduce liver fat largely through weight loss; glucagon acts on hepatocytes directly. Whether survodutide's histological benefit is more than a weight effect is the question the mediation analysis addresses [8], and the phase 3 MASLD trial's separation of liver fat reduction (84.2% versus 24.3%) from body weight change (-12.2% versus -1.0%) is at least suggestive that it is [3].

A once-weekly subcutaneous injection. Acylation to a C18 fatty diacid gives albumin binding and the weekly half-life, the same strategy used in semaglutide [4].

The gastrointestinal burden is at the high end of the class. In the MASH trial, nausea occurred in 66% against 23% on placebo, diarrhoea in 49% against 23%, and vomiting in 41% against 4%; serious adverse events were 8% against 7% [2]. In the phase 2 obesity trial, adverse events affected 91% of survodutide recipients against 75% on placebo, primarily gastrointestinal in 75% against 42% [1]. Completion of that 46-week trial was 61% on drug and 60% on placebo - so the dropout was not obviously drug-driven, but the numbers are low on both arms.

The glucagon question. Glucagon receptor agonism raises the theoretical possibility of worse glycaemia and a higher heart rate. In the trials to date, HbA1c fell rather than rose [7]. Heart rate effects have not been a headline finding in the published abstracts, but this is a mechanism that warrants long-term cardiovascular data, and none exists: no cardiovascular outcome trial has reported.

A phase 1 trial in cirrhosis found the drug tolerable in people with impaired liver function [9], which is reassuring for the population it is aimed at.

Class-wide precautions - perioperative gastric emptying, hypoglycaemia with insulin or sulfonylureas - should be assumed [10][11].

No dedicated interaction studies have been published. In the phase 2 diabetes trial, semaglutide was an open-label comparator rather than a combination [7].

Class considerations apply: delayed gastric emptying slows oral drug absorption, and combination with insulin or a sulfonylurea raises hypoglycaemia risk.